H
Heather A. Jacene
Researcher at Harvard University
Publications - 152
Citations - 8497
Heather A. Jacene is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 29, co-authored 128 publications receiving 6869 citations. Previous affiliations of Heather A. Jacene include Brigham and Women's Hospital & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
TL;DR: Qualitative and quantitative approaches to 18F-FDG PET response assessment have been applied and require a consistent PET methodology to allow quantitative assessments and the proposed PERCIST 1.0 criteria should serve as a starting point for use in clinical trials and in structured quantitative clinical reporting.
Journal ArticleDOI
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan R. Strosberg,Ghassan El-Haddad,Edward M. Wolin,Andrew Eugene Hendifar,James C. Yao,Beth Chasen,Erik Mittra,Pamela L. Kunz,Matthew H. Kulke,Heather A. Jacene,David L. Bushnell,Thomas M. O'Dorisio,Richard A. Baum,Harshad R. Kulkarni,Martyn Caplin,Rachida Lebtahi,Timothy J. Hobday,Ebrahim S. Delpassand,E. Van Cutsem,Al B. Benson,Raj Srirajaskanthan,Marianne Pavel,J. Mora,Jordan Berlin,Enrique Grande,N. Reed,Ettore Seregni,Kjell Öberg,M. Lopera Sierra,P. Santoro,Thomas Thevenet,Jack L. Erion,Philippe Ruszniewski,Dirk Jan Kwekkeboom,E.P. Krenning +34 more
TL;DR: Treatment with lutetium‐177 (177Lu)–Dotatate resulted in markedly longer progression‐free survival and a significantly higher response rate than high‐dose octreotide LAR among patients with advanced midgut neuroendocrine tumors.
Journal ArticleDOI
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.
Bruce D. Cheson,Stephen M. Ansell,Lawrence H. Schwartz,Leo I. Gordon,Ranjana H. Advani,Heather A. Jacene,Axel Hoos,Sally F. Barrington,Philippe Armand +8 more
TL;DR: A workshop was convened to provide provisional recommendations to modify current response criteria in patients receiving immunomodulatory agents in clinical trials, and the term "indeterminate response" was introduced to identify such lesions until confirmed as flare/pseudo-progression or true PD by either biopsy or subsequent imaging.
Journal ArticleDOI
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
Jonathan D. Schoenfeld,Jonathan D. Schoenfeld,Glenn J. Hanna,Glenn J. Hanna,Vickie Y. Jo,Bhupendra Rawal,Yu-Hui Chen,P.S. Catalano,Ana Lako,Ana Lako,Zoe B. Ciantra,Jason L. Weirather,Shana Criscitiello,Shana Criscitiello,Adrienne M. Luoma,Nicole G. Chau,Jochen H. Lorch,Jochen H. Lorch,Jason I. Kass,Jason I. Kass,Donald J. Annino,Donald J. Annino,Laura A. Goguen,Laura A. Goguen,Anupam M. Desai,Brendan Ross,Brendan Ross,Hina Shah,Heather A. Jacene,Danielle N. Margalit,Danielle N. Margalit,Roy B. Tishler,Roy B. Tishler,Kai W. Wucherpfennig,Scott J. Rodig,Scott J. Rodig,Ravindra Uppaluri,Ravindra Uppaluri,Robert I. Haddad,Robert I. Haddad +39 more
TL;DR: Novel approaches are needed to improve outcomes in patients with squamous cell carcinoma of the oral cavity and promising rates of response in both arms are observed, supporting further neoadjuvant studies with these agents.
Journal ArticleDOI
CT Hounsfield Units of Brown Adipose Tissue Increase with Activation: Preclinical and Clinical Studies
TL;DR: The CT HUs of BAT increased in activated conditions in both animals and patients, likely because of lipid consumption by activated BAT.